Trodelvy did not meet the primary endpoint of progression-free survival in the ASCENT-07 trial for HR-positive, HER2-negative ...
Camizestrant combined with CDK4/6 inhibitors shows antitumor activity and is well-tolerated in ER+, HER2– advanced breast ...
Gilead announces phase 3 ASCENT-07 study of Trodelvy versus chemotherapy to treat post-endocrine therapy in HR+/HER2-negative metastatic breast cancer fails to meet the primary en ...
MedPage Today on MSN
Better Therapy, Care in Advanced Breast Cancer Has Led to Longer Survival
Patients with HER2-positive advanced breast cancers had the greatest benefits, with survival improvements ranging from ...
A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still ...
In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.
Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...
A retrospective hospital-based study was conducted between January 2018 and May 2021 at two prominent public tertiary hospitals in Tanzania. The primary outcome was the 5-year overall survival (OS) ...
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback